KR20040004629A - ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법 - Google Patents

ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법 Download PDF

Info

Publication number
KR20040004629A
KR20040004629A KR10-2003-7014985A KR20037014985A KR20040004629A KR 20040004629 A KR20040004629 A KR 20040004629A KR 20037014985 A KR20037014985 A KR 20037014985A KR 20040004629 A KR20040004629 A KR 20040004629A
Authority
KR
South Korea
Prior art keywords
myc
administration
antisense
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7014985A
Other languages
English (en)
Korean (ko)
Inventor
이버슨패트릭엘.
Original Assignee
에이브이아이 바이오파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이브이아이 바이오파마 인코포레이티드 filed Critical 에이브이아이 바이오파마 인코포레이티드
Publication of KR20040004629A publication Critical patent/KR20040004629A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-2003-7014985A 2001-05-17 2002-05-17 ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법 Ceased KR20040004629A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29172701P 2001-05-17 2001-05-17
US60/291,727 2001-05-17
PCT/US2002/015842 WO2002092617A1 (en) 2001-05-17 2002-05-17 Combined approach to treatment of cancer using a c-myc antisense oligomer

Publications (1)

Publication Number Publication Date
KR20040004629A true KR20040004629A (ko) 2004-01-13

Family

ID=23121574

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7014985A Ceased KR20040004629A (ko) 2001-05-17 2002-05-17 ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법

Country Status (8)

Country Link
US (1) US20030087861A1 (https=)
EP (1) EP1399462A4 (https=)
JP (1) JP2004537517A (https=)
KR (1) KR20040004629A (https=)
CN (1) CN1509292A (https=)
CA (1) CA2447052A1 (https=)
NZ (1) NZ530101A (https=)
WO (1) WO2002092617A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016048054A3 (ko) * 2014-09-24 2016-05-12 삼성전자 주식회사 데이터 통신 보안을 위한 방법, 장치 및 시스템

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640582B2 (en) 2003-04-16 2009-12-29 Silicon Graphics International Clustered filesystem for mix of trusted and untrusted nodes
CA2523672C (en) * 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
WO2006058038A2 (en) * 2004-11-22 2006-06-01 The Research Foundation Of State University Of New York At Buffalo In vitro and in vivo silencing of human c-myc oncogene expression by poly-dnp-rna
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007065017A2 (en) * 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Oligonucleotide cationic liposomal delivery system
CA2631677C (en) 2005-12-01 2014-08-12 Pronai Therapeutics, Inc. Amphoteric liposome formulation
EP1971371B1 (en) * 2005-12-01 2015-08-05 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
US20070270371A1 (en) * 2006-03-31 2007-11-22 Brown Bob D Dosing and scheduling of oligomers
DK2735568T3 (da) * 2006-05-10 2017-11-13 Sarepta Therapeutics Inc Oligonukleotidanaloger med kationiske bindinger mellem underenheder
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP3443976A1 (en) * 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN101624596B (zh) * 2009-08-12 2011-01-26 广州金琪基因技术研究发展中心 一种靶向c-myc癌基因的外指引序列
KR20200133284A (ko) 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
EA202090338A1 (ru) 2011-11-18 2021-04-30 Сарепта Терапьютикс, Инк. Функционально-модифицированные олигонуклеотиды и их субъединицы
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
SMT202200366T1 (it) 2016-12-19 2022-11-18 Sarepta Therapeutics Inc Coniugati di oligomeri per salto di esone per distrofia muscolare
CN108338986B (zh) * 2017-01-23 2020-04-03 深圳开悦生命科技有限公司 一种用于治疗癌症的小分子rna及其应用
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC, CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RAILS
EP3840758A1 (en) * 2018-08-21 2021-06-30 Deep Genomics Incorporated Therapeutic splice-switching oligonucleotides
CA3126432A1 (en) * 2019-02-01 2020-08-06 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
US20250289851A1 (en) 2022-04-22 2025-09-18 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
EP4665407A2 (en) * 2023-02-14 2025-12-24 Stoke Therapeutics, Inc. Antisense oligomer formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515781A (en) * 1983-02-23 1985-05-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 2',5'-Riboadenylate-morpholinoadenylate nucleotides
US6544755B1 (en) * 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
ATE208634T1 (de) * 1993-01-07 2001-11-15 Univ Jefferson Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
EP0932698A1 (en) * 1996-03-26 1999-08-04 Lynx Therapeutics, Inc. Oligonucleotide treatments and compositions for human melanoma
US6784291B2 (en) * 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016048054A3 (ko) * 2014-09-24 2016-05-12 삼성전자 주식회사 데이터 통신 보안을 위한 방법, 장치 및 시스템

Also Published As

Publication number Publication date
EP1399462A4 (en) 2008-03-05
NZ530101A (en) 2007-01-26
US20030087861A1 (en) 2003-05-08
CN1509292A (zh) 2004-06-30
EP1399462A1 (en) 2004-03-24
WO2002092617A1 (en) 2002-11-21
CA2447052A1 (en) 2002-11-21
JP2004537517A (ja) 2004-12-16

Similar Documents

Publication Publication Date Title
KR20040004629A (ko) ｃ-ｍｙｃ 안티센스 올리고머를 사용한 암치료를 위한조합 접근법
JP2024128025A (ja) ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用
KR0171210B1 (ko) 암치료용 항감작 올리고뉴클레오티드
JP7003044B2 (ja) Ａｎｇｐｔ２およびｐｄｇｆｂを標的化するｒｎａ複合体を用いる血管新生関連疾患の処置
Thomas et al. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models
US20160201064A1 (en) Compositions and methods for modulating expression of frataxin
CN102481364A (zh) 用her2受体拮抗剂联合7-乙基-10-羟基喜树碱的多臂聚合缀合物治疗her2阳性癌症的方法
JP6949859B2 (ja) Ｄｂａｉｔ分子の全身投与によるガンの処置
Tian et al. Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39
JP7291418B2 (ja) Ｐｃｓｋ９を標的としたアンチセンス核酸
KR101142080B1 (ko) 전립선암 및 다른 암의 치료 방법 및 조성물
KR20240161203A (ko) 엔젤만 증후군 안티센스 치료
US20110312528A1 (en) Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
US20170211073A1 (en) Antisense antineoplastic agent
WO2020160453A1 (en) Modulators of yap1 expression
CN112996568A (zh) 用于调节mir-10b活性的微小rna化合物和方法
US20210395752A1 (en) Vdac1 silencing molecules and use thereof
US20180235936A1 (en) Cancer treatment methods
US20050113328A1 (en) Method and antisense compound for potentiating anti-cancer agents
KR20180068524A (ko) SS18-SSX 융합 유전자 특이적 siRNA 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물
JP2004528851A (ja) 上皮成長因子受容体のアンチセンスオリゴヌクレオチド
JP2004528851A6 (ja) 上皮成長因子受容体のアンチセンスオリゴヌクレオチド
AU2002308767A1 (en) Combined approach to treatment of cancer using a c-myc antisense oligomer
CN112654706B (zh) 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途
CN121773207A (zh) 用于癌症的tgfb2-irf5治疗剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20031117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070516

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080328

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080901

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080328

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I